• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血栓性血小板减少性紫癜患者血浆组织因子途径抑制物水平降低。

Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura.

作者信息

Kobayashi M, Wada H, Wakita Y, Shimura M, Nakase T, Hiyoyama K, Nagaya S, Minami N, Nakano T, Shiku H

机构信息

2nd Department of Internal Medicine, Mie University School of Medicine, Mie Ken, Japan.

出版信息

Thromb Haemost. 1995 Jan;73(1):10-4.

PMID:7740478
Abstract

We measured plasma levels of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in patients with thrombotic thrombocytopenic purpura (TTP) and disseminated intravascular coagulation (DIC) to examine the relationship between TFPI and vascular endothelial cell injury. TF antigen was detected in the plasma of healthy volunteers, and the levels were significantly increased in the patients with DIC, but decreased slightly in those with TTP. Plasma TFPI levels were significantly decreased in patients with TTP compared with those in healthy volunteers. The concentration of plasma thrombomodulin (TM) antigen was significantly higher in those with TTP than in normal volunteers. One month after treatment, TTP patients showed a significant decrease in plasma TM levels, and a significant increase in plasma TFPI levels, but plasma levels of TF antigen were not significantly increased. As plasma TFPI/TF ratio was significantly increased after treatment, the hypercoagulable state was therefore improved after treatment. There was no significant difference in plasma TF and TFPI levels between those who achieved complete remission (CR) and those who died. However, plasma TM levels were significantly higher in those who died than in those who achieved CR. Plasma TFPI levels might reflect injury of vascular endothelial cells as do plasma TM levels, and decreased plasma TFPI/TF ratio and vascular endothelial cell injuries might play causative roles in TTP.

摘要

我们检测了血栓性血小板减少性紫癜(TTP)和弥散性血管内凝血(DIC)患者血浆中组织因子(TF)和组织因子途径抑制物(TFPI)的水平,以研究TFPI与血管内皮细胞损伤之间的关系。在健康志愿者血浆中检测到TF抗原,DIC患者血浆中TF抗原水平显著升高,而TTP患者血浆中TF抗原水平略有下降。与健康志愿者相比,TTP患者血浆TFPI水平显著降低。TTP患者血浆血栓调节蛋白(TM)抗原浓度显著高于正常志愿者。治疗1个月后,TTP患者血浆TM水平显著下降,血浆TFPI水平显著升高,但TF抗原血浆水平未显著升高。由于治疗后血浆TFPI/TF比值显著升高,因此治疗后高凝状态得到改善。完全缓解(CR)者与死亡者的血浆TF和TFPI水平无显著差异。然而,死亡者的血浆TM水平显著高于CR者。血浆TFPI水平可能与血浆TM水平一样反映血管内皮细胞损伤,血浆TFPI/TF比值降低和血管内皮细胞损伤可能在TTP发病中起致病作用。

相似文献

1
Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜患者血浆组织因子途径抑制物水平降低。
Thromb Haemost. 1995 Jan;73(1):10-4.
2
Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.弥散性血管内凝血患者的血浆组织因子和组织因子途径抑制物水平
Am J Hematol. 1996 Jul;52(3):165-70. doi: 10.1002/(SICI)1096-8652(199607)52:3<165::AID-AJH5>3.0.CO;2-R.
3
[Plasma level of various markers in patients with thrombotic thrombocytopenic purpura].
Rinsho Ketsueki. 1994 Apr;35(4):346-51.
4
Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM).成人血栓性血小板减少性紫癜/溶血性尿毒症综合征(TTP/HUS)及骨髓移植相关血栓性微血管病(BMT-TM)中的血浆血管性血友病因子抗原(vWF:AG)和血栓调节蛋白(TM)水平
Am J Hematol. 1996 Dec;53(4):213-20. doi: 10.1002/(SICI)1096-8652(199612)53:4<213::AID-AJH1>3.0.CO;2-0.
5
Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries.弥散性血管内凝血或血栓性血小板减少性紫癜患者若伴有严重血管内皮细胞损伤,预后较差。
Am J Hematol. 1998 Jul;58(3):189-94. doi: 10.1002/(sici)1096-8652(199807)58:3<189::aid-ajh5>3.0.co;2-n.
6
[Analysis of behaviors of plasma tissue factor and tissue factor pathway inhibitor in patients with various diseases].[不同疾病患者血浆组织因子及组织因子途径抑制物的行为分析]
Rinsho Ketsueki. 1996 Sep;37(9):794-8.
7
Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.针对组织因子途径抑制物-因子Xa复合物的单克隆抗体:其特性及在弥散性血管内凝血和弥散性血管内凝血前期患者血浆中的应用
Blood Coagul Fibrinolysis. 1999 Sep;10(6):309-19.
8
Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.弥散性血管内凝血患者的血浆组织因子和组织因子途径抑制物水平
Am J Hematol. 1997 Aug;55(4):169-74. doi: 10.1002/(sici)1096-8652(199707)55:4<169::aid-ajh1>3.0.co;2-q.
9
Continuous intravenous infusion of dipyridamole as adjunctive therapy in the treatment of thrombotic thrombocytopenic purpura.持续静脉输注双嘧达莫作为血栓性血小板减少性紫癜治疗的辅助疗法。
Transfus Apher Sci. 2003 Oct;29(2):141-5. doi: 10.1016/S1473-0502(03)00118-6.
10
Increased P-selectin plasma levels in patients with thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜患者血浆中P-选择素水平升高。
Haematologica. 1996 Jan-Feb;81(1):3-7.

引用本文的文献

1
Is Endothelial Activation a Critical Event in Thrombotic Thrombocytopenic Purpura?内皮细胞活化是血栓性血小板减少性紫癜的关键事件吗?
J Clin Med. 2023 Jan 18;12(3):758. doi: 10.3390/jcm12030758.
2
Rare Defects: Looking at the Dark Face of the Thrombosis.罕见缺陷:审视血栓形成的黑暗面。
Int J Environ Res Public Health. 2021 Aug 30;18(17):9146. doi: 10.3390/ijerph18179146.
3
Tissue factor activity in women with preeclampsia or SGA: a potential explanation for the excessive thrombin generation in these syndromes.子痫前期或小于胎龄儿女性的组织因子活性:这些综合征中凝血酶过度生成的一种潜在解释。
J Matern Fetal Neonatal Med. 2018 Jun;31(12):1568-1577. doi: 10.1080/14767058.2017.1320543. Epub 2017 May 19.
4
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.甲状腺功能减退症患儿中凝血酶激活的纤溶抑制物增加,组织因子途径抑制物和血栓调节蛋白水平降低。
J Clin Res Pediatr Endocrinol. 2012 Sep;4(3):146-50. doi: 10.4274/Jcrpe.652.
5
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.甲状腺功能亢进症患者中凝血酶激活的纤溶抑制物增加和组织因子途径抑制物减少。
Endocrine. 2009 Dec;36(3):473-8. doi: 10.1007/s12020-009-9271-2. Epub 2009 Oct 27.
6
Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.库欣综合征患者的血液凝固与纤维蛋白溶解:纤溶酶原激活物抑制剂-1升高、组织因子途径抑制剂降低,凝血酶激活的纤维蛋白溶解抑制剂水平无变化。
J Endocrinol Invest. 2009 Feb;32(2):169-74. doi: 10.1007/BF03345709.
7
Tissue factor and its natural inhibitor in pre-eclampsia and SGA.子痫前期和小于胎龄儿中的组织因子及其天然抑制剂
J Matern Fetal Neonatal Med. 2008 Dec;21(12):855-69. doi: 10.1080/14767050802361872.
8
Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.肢端肥大症患者的血液凝固与纤维蛋白溶解:纤溶酶原激活物抑制剂-1(PAI-1)增加,组织因子途径抑制剂(TFPI)减少,且生长激素与TFPI呈负相关。
Endocrine. 2008 Jun;33(3):270-6. doi: 10.1007/s12020-008-9088-4.
9
A link between a hemostatic disorder and preterm PROM: a role for tissue factor and tissue factor pathway inhibitor.止血障碍与早产胎膜早破之间的联系:组织因子和组织因子途径抑制剂的作用。
J Matern Fetal Neonatal Med. 2008 Oct;21(10):732-44. doi: 10.1080/14767050802361807.
10
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.甲状腺功能减退患者中凝血酶激活的纤维蛋白溶解抑制剂增加,组织因子途径抑制剂减少。
Endocrine. 2009 Feb;35(1):75-80. doi: 10.1007/s12020-008-9116-4. Epub 2008 Oct 29.